<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24346879</article-id>
      <article-id pub-id-type="pmc">3876002</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20132578</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Cowden Syndrome: report of a case and brief review of literature<xref ref-type="fn" rid="fn01">*</xref>
</article-title>
        <trans-title-group xml:lang="pt">
          <trans-title>S&#xED;ndrome de Cowden: Relato de caso e uma breve revis&#xE3;o da
literatura</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Porto</surname>
            <given-names>Ana Carolina Souza</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Roider</surname>
            <given-names>Elisabeth</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ruzicka</surname>
            <given-names>Thomas</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
      </contrib-group>
      <aff id="aff01"><label>1</label> Residents in Dermatology - Medical Department of Dermatology and
Allergy, Ludwig-Maximilian University of Munich, Germany.</aff>
      <aff id="aff02"><label>2</label> Director of the Department of Dermatology and Allergy,
Ludwig-Maximilian University of Munich, Germany.</aff>
      <author-notes>
        <corresp id="c01"><bold>Mailing address:</bold> Ana Carolina Souza Porto, Rua Loegreen, 1654 - Apt. 71,
04040-002 - Sao Paulo - SP, Brazil. E-mail: <email>carolsporto1@hotmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Nov-Dec</season>
        <year>2013</year>
      </pub-date>
      <volume>88</volume>
      <issue>6 Suppl 1</issue>
      <fpage>52</fpage>
      <lpage>55</lpage>
      <history>
        <date date-type="received">
          <day>27</day>
          <month>2</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>02</day>
          <month>5</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2013 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>We present the case of a female patient with facial cutaneous lesions, a
cobblestone-like pattern of the oral mucosa, and verruciform lesions on the hand
since her youth. She reported a history of breast cancer, endometrial cancer,
melanoma and multiple benign tumors and cysts. PTEN gene analysis was performed and
confirmed Cowden Syndrome, a rare genodermatosis with an autosomal dominant pattern
of inheritance, characterized by multiple hamartomas. The phosphatase and tensin
homolog (PTEN) gene negatively regulates cell proliferation and cell cycle
progression. Loss of PTEN function contributes to an increased risk of cancer. We
emphasize the importance of early detection and accurate management of Cowden
Syndrome.</p>
      </abstract>
      <trans-abstract xml:lang="pt">
        <p>Apresentamos o caso de uma paciente com les&#xF5;es cut&#xE2;neas faciais, mucosa oral com
apar&#xEA;ncia de paralelep&#xED;pedo, e les&#xF5;es de aspecto verrucoso na m&#xE3;o desde a sua
juventude. Ela relatou uma hist&#xF3;ria de c&#xE2;ncer de mama, c&#xE2;ncer de endom&#xE9;trio, melanoma
e m&#xFA;ltiplos tumores benignos e cistos. A an&#xE1;lise gen&#xE9;tica PTEN foi realizada e
confirmou a S&#xED;ndrome de Cowden, uma genodermatose rara, com um padr&#xE3;o de heran&#xE7;a
autoss&#xF4;mica dominante, caracterizada por m&#xFA;ltiplos hamartomas. O gene hom&#xF3;logo de
fosfatase e angiotensina (PTEN) regula negativamente a prolifera&#xE7;&#xE3;o celular e a
progress&#xE3;o do ciclo celular. A perda da fun&#xE7;&#xE3;o PTEN contribui para um aumento do
risco de c&#xE2;ncer. Ressaltamos a import&#xE2;ncia da detec&#xE7;&#xE3;o precoce e tratamento preciso
da S&#xED;ndrome de Cowden.</p>
      </trans-abstract>
      <kwd-group>
        <kwd>Breast neoplasms</kwd>
        <kwd>Genes, neoplasm</kwd>
        <kwd>Hamartoma syndrome, multiple</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>INTRODUCTION</title>
      <p>Cowden syndrome (CS), also known as multiple hamartoma syndrome, is a rare
genodermatosis with an autosomal dominant pattern of inheritance.<sup><xref ref-type="bibr" rid="r01">1</xref></sup> CS is the best described PTEN hamartoma
tumor syndrome (PHTS). PHTS is a group of disorders that have in common a disorganized
growth of native cells in native tissues and includes CS, Bannayan-Riley-Ruvalcaba
syndrome (BRRS), Lhermitte-Duclos disease (LDD), Proteus and Proteus-like
syndrome.<sup><xref ref-type="bibr" rid="r02">2</xref></sup> CS is the only PHTS
disorder associated with a documented predisposition to malignancies.<sup><xref ref-type="bibr" rid="r01">1</xref></sup> Early diagnosis of CS is difficult due to
the highly variable expressivity of signs and symptoms, in addition to the rarity of the
disease.<sup><xref ref-type="bibr" rid="r01">1</xref>,<xref ref-type="bibr" rid="r02">2</xref>,<xref ref-type="bibr" rid="r03">3</xref></sup>
</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A 59-year-old female patient presented with a lifelong history of carcinoma and unclear
cutaneous and mucocutaneous lesions. Clinical investigation showed firm, flat-topped,
yellowish papules in the periorbital region and tiny whitish papules of the oral mucosa
(<xref ref-type="fig" rid="f01">Figure 1</xref>). Multiple hyperkeratotic verruciform
lesions on the back of the hand and palmar pits were found (<xref ref-type="fig" rid="f02">Figure 2</xref>). A macrocephaly above the 97<sup>th</sup> percentile was
diagnosed. The patient's history included breast cancer at the age of 34, an endometrial
carcinoma at age 46 and a recently diagnosed malignant melanoma. Furthermore, the
patient reported adenomas of thyroid, recurrent gastrointestinal polyps and cutaneous
lipomas and trichilemmomas. She also suffered from kidney cysts, cysts of the fallopian
tube, cataract, osteoporosis and diffuse hair loss. Her family history showed no
incidence of multiple hamartoma syndrome. </p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>
<bold>A.</bold> Small yellowish papules of flat top around the eye.
<bold>B.</bold> Papular lesions on the lips with characteristic
cobblestone-like pattern</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0052-g01"/>
      </fig>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>
<bold>A.</bold> Acral hyperkeratoses. <bold>B.</bold> Palmar pits</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0052-g02"/>
      </fig>
      <p>Laboratory testing and organ examination did not show any pathologic findings. Histology
of one periorbital lesion showed a symmetrical epithelial nodular proliferation with
mild papillomatosis, overlying hiperkeratosis and downgrowth of epithelial cells with
clear cell differentiation. Histology of one back-of-hand lesion showed regular
ortho-and hyperkeratosis (<xref ref-type="fig" rid="f03">Figures 3</xref> and <xref ref-type="fig" rid="f04">4</xref>). Genetic analysis finally confirmed heterozygous
deletion of nucleotide 968 in exon 8 of the PTEN gene, located on chromosome 10. </p>
      <fig id="f03" orientation="portrait" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>Skin biopsy of the periorbital region showed a nodular proliferation with
papillomatosis, overlying hyperkeratosis and downgrowth of epithelial cells
presenting a tricholemmoma</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0052-g03"/>
      </fig>
      <fig id="f04" orientation="portrait" position="float">
        <label>FIGURE 4</label>
        <caption>
          <p>Skin biopsy of one back-of-hand lesion showed regular ortho-and hyperkeratosis</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0052-g04"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>CS, also known as multiple hamartoma syndrome, was first described in 1963 by Lloyd and
Dennis, referring to their patient Rachael Cowden.<sup><xref ref-type="bibr" rid="r01">1</xref>,<xref ref-type="bibr" rid="r04">4</xref></sup> This syndrome is a
genetic disorder characterized by a broad range of symptoms and signs, including
multiple cutaneous/mucocutaneous lesions and involvement of different organs, leading to
a massive cumulative lifetime risk of cancer.<sup><xref ref-type="bibr" rid="r02">2</xref>,<xref ref-type="bibr" rid="r03">3</xref>,<xref ref-type="bibr" rid="r04">4</xref></sup> Although data is limited, the estimated prevalence of CS is
1/200,000.<sup><xref ref-type="bibr" rid="r01">1</xref>,<xref ref-type="bibr" rid="r03">3</xref>,<xref ref-type="bibr" rid="r04">4</xref></sup> However, the
true prevalence may be greater because many of the CS features occur also in the general
population.<sup><xref ref-type="bibr" rid="r01">1</xref></sup> Both sexes can be
affected, although a slight female predominance has been observed. CS is most often
diagnosed during the third decade of life. The age of onset may however vary from 4 to
75 years.<sup><xref ref-type="bibr" rid="r04">4</xref>,<xref ref-type="bibr" rid="r05">5</xref></sup>
</p>
      <p>Most patients with CS have a germ-line mutation in the tumor suppressor gene phosphatase
and tensin homologue (PTEN), located on chromosome 10q23. The PTEN tumor suppressor gene
encodes a phosphatase, which is a negative regulator of PI3KAKT and mTOR signaling
pathways, and controls cell proliferation, cell cycle progression, and
apoptosis.<sup><xref ref-type="bibr" rid="r02">2</xref>,<xref ref-type="bibr" rid="r06">6</xref></sup> The loss of PTEN function contributes to cellular
transformation and increases the risk of cancer development in many organs. More than
100 different germline mutations of the PTEN have been reported, but no significant
correlation has been found between the specific mutation type and the occurrence of
different types of cancer or non-malignant clinical features.<sup><xref ref-type="bibr" rid="r02">2</xref></sup> In addition, 20% of CS patients have no identifiable
mutation.<sup><xref ref-type="bibr" rid="r03">3</xref>,<xref ref-type="bibr" rid="r07">7</xref></sup>
</p>
      <p>Although expression of the disease is variable, cutaneous lesions are common and
pathognomon<sup><xref ref-type="bibr" rid="r05">5</xref>,<xref ref-type="bibr" rid="r07">7</xref></sup> Usually these lesions are the first signal in CS patients
and therefore may serve as first clue for early diagnosis before severe malignancies
develop.<sup><xref ref-type="bibr" rid="r08">8</xref>,<xref ref-type="bibr" rid="r09">9</xref></sup> In over 90% of CS patients pathognomonic cutaneous
lesions such as trichilemmomas, acral keratoses, pits on the palms and soles, and
papular lesions on the lips and oral mucosa with a characteristic cobblestone-like
pattern develop.<sup><xref ref-type="bibr" rid="r07">7</xref>,<xref ref-type="bibr" rid="r08">8</xref></sup> Lipomas are also a common finding in CS. All of these
lesions were found in the case described in this report. </p>
      <p>The most frequently reported extracutaneous manifestation of CS is thyroid disease,
which occurs in up to 75% of cases.<sup><xref ref-type="bibr" rid="r01">1</xref>,<xref ref-type="bibr" rid="r04">4</xref>,<xref ref-type="bibr" rid="r08">8</xref></sup>
This may manifest as benign multinodular goiter, lymphocytic thyreoiditis, adenomas or
thyroid dysfunction. Thyroid cancer occurs in 3 to 10 % of patients and represents the
second most common cancer in CS.<sup><xref ref-type="bibr" rid="r01">1</xref>,<xref ref-type="bibr" rid="r09">9</xref>,<xref ref-type="bibr" rid="r10">10</xref></sup>
These cancers are exclusively of a follicular or papillary type.<sup><xref ref-type="bibr" rid="r10">10</xref></sup>
</p>
      <p>Breast lesions occur in almost 75 % of all women suffering from CS and usually manifest
as fibrocystic disease.<sup><xref ref-type="bibr" rid="r04">4</xref>,<xref ref-type="bibr" rid="r08">8</xref></sup> Breast cancer is the most common
malignancy of CS and the most important cause of death, leading to a cumulated risk of
77 % at the age of 70.<sup><xref ref-type="bibr" rid="r02">2</xref></sup>
</p>
      <p>Macrocephaly is a common finding in CS patients, present in approximately 80 % of
patients with CS.<sup><xref ref-type="bibr" rid="r01">1</xref></sup> Polyps of the
gastrointestinal tract occur in at least 50 % of CS patients, leading to an increased
risk for colorectal cancer.<sup><xref ref-type="bibr" rid="r01">1</xref>,<xref ref-type="bibr" rid="r04">4</xref>,<xref ref-type="bibr" rid="r06">6</xref></sup>
Endometrial cancer occurs in 5% to 10 % of all women with CS.<sup><xref ref-type="bibr" rid="r10">10</xref></sup> Other common findings include benign ovarian cysts,
neurologic malformations, mental retardation and an immune dysfunction. Interestingly, a
recent study showed a melanoma prevalence of 6 % in CS patients.<sup><xref ref-type="bibr" rid="r02">2</xref></sup>
</p>
      <p>The diagnosis of CS is eminently clinical, based on criteria proposed by the
International Cowden Syndrome Consortium (<xref ref-type="table" rid="t01">Chart
1</xref>).<sup><xref ref-type="bibr" rid="r01">1</xref></sup> As can be seen in <xref ref-type="table" rid="t01">chart 1</xref>, our patient presented multiple
pathognomonic lesions and major and minor criteria. </p>
      <table-wrap id="t01" orientation="portrait" position="float">
        <label>CHART 1</label>
        <caption>
          <p>Diagnostic criteria proposed by the International Cowden Syndrome Consortium
(ICSC). (Underlined criteria are presented by the patient)</p>
        </caption>
        <table frame="box" rules="groups">
          <thead>
            <tr>
              <td rowspan="1" colspan="1">
<bold>Diagnostic criteria proposed by the International Cowden Syndrome
Consortium (ICSC)</bold>
</td>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">
<bold>Pathognomonic lesions</bold>
</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">(1 required)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#x2022; Six or more facial papules (&#x2265; 3 trichilemmomas)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#x2022; Facial cutaneous papules + papillomatosis of the oral mucosa</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#x2022; Papillomatosis of the oral mucosa + acral keratosis</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#x2022; &#x2265; 6 palmoplantar keratoses</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#xA0;</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
<bold>Major criteria</bold>
</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">(2 required, one must be macrocephaly or Lhermitte-Duclos disease)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#x2022; Breast carcinoma</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#x2022; Thyroid carcinoma</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#x2022; Macrocephaly (&gt;97%)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#x2022; Lhermitte-Duclos disease</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#x2022; Endometrial carcinoma</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#xA0;</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
<bold>Minor criteria</bold>
</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">(4 required)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#x2022; Thyroid lesions (other than carcinoma)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#x2022; Learning difficulties or delayed development</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#x2022; Gastrointestinal hamartomas</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#x2022; Lipomas</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#x2022; Fibromas</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#x2022; Fibrocystic disease of the breast</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#x2022; Genitourinary malformations or carcinoma</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#xA0;</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">One major criterion and three minor criteria may also indicate a diagnosis
of Cowden Syndrome</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn>
            <p>Adapted from: Mukamal LV, <italic>et al.</italic>
<sup><xref ref-type="bibr" rid="r09">9</xref></sup>
</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>Management of Cowden Syndrome includes early detection of malignant conditions, patient
education, genetic counseling, and regular surveillance.<sup><xref ref-type="bibr" rid="r06">6</xref></sup> Given the high risk of malignancy, cancer surveillance is
the major focus of medical management. The National Comprehensive Cancer Network (NCCN)
provides regularly updated guidelines that outline a cancer surveillance program for men
and women with Cowden Syndrome (<xref ref-type="table" rid="t02">Chart
2</xref>).<sup><xref ref-type="bibr" rid="r01">1</xref>,<xref ref-type="bibr" rid="r09">9</xref></sup>
</p>
      <table-wrap id="t02" orientation="portrait" position="float">
        <label>CHART 2</label>
        <caption>
          <p>Management of Cowden Syndrome</p>
        </caption>
        <table frame="box" rules="groups">
          <thead>
            <tr>
              <td rowspan="1" colspan="1">
<bold>Management of Cowden Syndrome</bold>
</td>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">
<bold>Women</bold>
</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#x2022; Breast self-examination starting at age 18.</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#x2022; Clinical breast exam starting at age 25 or 5-10 years before the earliest
breast cancer in the family occurred.</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#x2022; Patient education about endometrial cancer symptoms and clinical
screening.</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#x2022; Discussion of prophylactic mastectomy and hysterectomy.</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#xA0;</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
<bold>Men and women</bold>
</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#x2022; Annual physical examination starting at age 18 or 5 years before the
youngest age of cancer in family history.</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#x2022; Thyroid ultrasound at age 18, then once a year.</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#x2022; Colonoscopy, starting at the age of 35, then every 5 to 10 years.</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#x2022; Annual dermatologic exam.</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#xA0;</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
<bold>Risk to relatives</bold>
</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#x2022; Explain possible inherited cancer risks to relatives, options for risk
assessment and management.</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#x2022; Provide genetic counseling.</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn>
            <p>
<bold>Adapted from: </bold> The National Comprehensive Cancer Network
(NCCN).<sup><xref ref-type="bibr" rid="r01">1</xref></sup>
</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>All in all, it would appear that a large gap exists between the estimated prevalence and
the actual diagnosed number of patients with CS. We hope that this report will serve to
emphasize the importance of careful clinical investigation, so that appropriate
surveillance and risk management actions can be taken for the benefit of these patients.
Our patient reached 59 before being diagnosed with CS.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn id="fn01" fn-type="other">
        <p>* Work performed at the Department of Dermatology and Allergy, Ludwig-Maximilian
University - Munich, Germany.</p>
      </fn>
      <fn id="fn02" fn-type="conflict">
        <p>Conflict of interest: None</p>
      </fn>
      <fn id="fn03" fn-type="financial-disclosure">
        <p>Financial Support: None</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES </title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <collab>The National Comprehensive Cancer Network (NCCN)</collab>
          </person-group>
          <source>Clinical Practice Guidelines in Oncology.Genetic/Familial High-Risk
Assessment: Breast and Ovarian Cancer. Version 1.2012</source>
          <publisher-loc>New York</publisher-loc>
          <publisher-name>NCCN</publisher-name>
          <year>2012</year>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bubien</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Bonnet</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Brouste</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Hoppe</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Barouk-Simonet</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>David</surname>
              <given-names>A</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>High cumulative risks of cancer in patients with PTEN hamartoma tumour
syndrome</article-title>
          <source>J Med Genet</source>
          <year>2013</year>
          <volume>50</volume>
          <fpage>255</fpage>
          <lpage>263</lpage>
          <pub-id pub-id-type="pmid">23335809</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Melb&#xE2;rde-Gorku&#xF0;a</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Irmejs</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>B&#xE7;rzi&#xF2;a</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Strumfa</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Aboli&#xF2;&#xF0;</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gardovskis</surname>
              <given-names>A</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Challenges in the management of a patient with Cowden Syndrome: case
report and literature review</article-title>
          <source>Hered Cancer Clin Pract</source>
          <year>2012</year>
          <volume>10</volume>
          <fpage>5</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">22503188</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hammami</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Berriche</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Ali</surname>
              <given-names>HB</given-names>
            </name>
            <name>
              <surname>Hellara</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Ansar</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Mahjoub</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Managing the risk of cancer in Cowden Syndrome: a case
report</article-title>
          <source>J Med Case Rep</source>
          <year>2012</year>
          <volume>6</volume>
          <fpage>225</fpage>
          <lpage>225</lpage>
          <pub-id pub-id-type="pmid">22846627</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Masmoudi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chermi</surname>
              <given-names>ZM</given-names>
            </name>
            <name>
              <surname>Marrekchi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Raida</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Boudaya</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mseddi</surname>
              <given-names>M</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Cowden Syndrome</article-title>
          <source>J Dermatol Case Rep</source>
          <year>2011</year>
          <volume>5</volume>
          <fpage>8</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="pmid">21886759</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tutluer</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tanriover</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Guven</surname>
              <given-names>GS</given-names>
            </name>
          </person-group>
          <article-title>Cowden Syndrome: a major indication for extensive cancer
surveillance</article-title>
          <source>Med Oncol</source>
          <year>2012</year>
          <volume>29</volume>
          <fpage>1365</fpage>
          <lpage>1368</lpage>
          <pub-id pub-id-type="pmid">21394636</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Amer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mostafa</surname>
              <given-names>FF</given-names>
            </name>
            <name>
              <surname>Attwa</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Ibrahim</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Cowden's Syndrome: a clinical, immunological, and histopathological
study</article-title>
          <source>Int J Dermatol</source>
          <year>2011</year>
          <volume>50</volume>
          <fpage>516</fpage>
          <lpage>521</lpage>
          <pub-id pub-id-type="pmid">21506964</pub-id>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kovich</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Cowden's Syndrome</article-title>
          <source>Dermatol Online J</source>
          <year>2004</year>
          <volume>10</volume>
          <fpage>3</fpage>
          <lpage>3</lpage>
          <pub-id pub-id-type="pmid">15748573</pub-id>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mukamal</surname>
              <given-names>LV</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Jacques Cde</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Amorim</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Pineiro-Maceira</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ramose-Silva</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Cowden Syndrome: review and report of a case of late
diagnosis</article-title>
          <source>Int J Dermatol</source>
          <year>2012</year>
          <volume>51</volume>
          <fpage>1494</fpage>
          <lpage>1499</lpage>
          <pub-id pub-id-type="pmid">23171017</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pilarski</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Cowden Syndrome: a critical review of the clinical
literature</article-title>
          <source>J Genet Couns</source>
          <year>2009</year>
          <volume>18</volume>
          <fpage>13</fpage>
          <lpage>27</lpage>
          <pub-id pub-id-type="pmid">18972196</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
